Company Performance Metrics
- Anil Singhal: President & CEOPast Role: Adicet Bio, CEO
- Thomas Jahn: Chief Medical OfficerPast Role: Apexigen, Vice President, Clinical Development
Trishula is a privately held company dedicated to the development of TTX-030, a first-in-class, anti-CD39 antibody, in collaboration with AbbVie. TTX-030 inhibits the activity of CD39, an enzyme that converts ATP to AMP, the initial step in the generation of adenosine in the tumor microenvironment. TTX-030 prevents the formation of
immune-suppressive extracellular adenosine and maintains high levels of immune-activating extracellular ATP, stimulating dendritic and myeloid-derived cells necessary for both innate and adaptive immunity.
Currently, TTX-030 is being studied in phase 1/1b clinical trials as a monotherapy and in combination with an anti-PD-1 agent and standard chemotherapy in adults with advanced cancer (NCT03884556 and NCT04306900).
